Screening for High Frequency Malignant Disease
← catalyst calendarNCT05117840 · readout in 134 d
Sponsored by Guardant Health, Inc. (industry) · GH — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
12,000estimated
Sites
143
Countries
France, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-01-13 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lung Cancer
Intervention
- Device: Low-dose CT scan
Primary outcome
what the primary-completion date above is the date OFPerformance characteristics of Guardant LUNAR-2 test
measured 36 months
Permalink · GH's whole pipeline · Catalyst calendar · Every registered study · What changed